BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Patients can now benefit from same-day procedure to diagnose and treat lung cancer

Imagine being diagnosed with lung cancer and having the tumor surgically removed on the same day, thereby increasing the opportunity for limited follow-up ...

February 22, 2022 | News

First Proton Therapy Treatment Delivered in Southeast Asia

The Varian ProBeam uses sophisticated imaging to see, adapt, and deliver treatment to the designated site, using a powerful particle accelerator called the...

February 09, 2022 | News

mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN

New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine ...

February 08, 2022 | News

LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology

Scripps Research is the top nonprofit scientific institute in the US for producing high-quality research based on discoveries published in leading scientif...

February 04, 2022 | News

Debiopharm and Aspen Partner to launch prostate cancer drug trelstar® in South Africa

In 2020, nearly 14,000 South African men were newly diagnosed with prostate cancer1 with an average of 5 men dying from the disease every day.2 I...

February 01, 2022 | News

Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer

Analysis of 1,000+ patients, with 12 months mean follow up, demonstrates clinical utility of Signatera for informing post-surgical treatment decisions &nb...

January 24, 2022 | News

GC Cell seeks to expand global availability of Immuncell-LC® for liver cancer

Rivaara Immune to lead development and commercialization in India GC Cell (KOSDAQ:144510) and Rivaara Immune Private Limited today announced that they hav...

January 05, 2022 | News

Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan

Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing tra...

January 04, 2022 | News

First Approval in Japan for the KEYTRUDA Plus LENVIMA Combination

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare (M...

December 29, 2021 | News

Regor Therapeutics announced authorization from the USFDA to proceed with Regor's Phase 1 clinical development plans for RGT-419B.

On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration ...

December 28, 2021 | News

Patients can now benefit from same-day procedure to diagnose and treat lung cancer

First Proton Therapy Treatment Delivered in Southeast Asia

mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN

LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology

Debiopharm and Aspen Partner to launch prostate cancer drug trelstar® in South Africa

Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer

GC Cell seeks to expand global availability of Immuncell-LC® for liver cancer

Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan

First Approval in Japan for the KEYTRUDA Plus LENVIMA Combination

Regor Therapeutics announced authorization from the USFDA to proceed with Regor's Phase 1 clinical development plans for RGT-419B.

Everest Medicines to treat Triple-Negative Breast Cancer in South Korea

Clarity and Cardinal Health to address the growing needs in oncology

World-first lung cancer screening facility increases chance of cure

Africa to benefit from advanced radiation therapy for cancer patients

Stay Connected